Infusion therapy in severe heart failure. A reappraisal.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Decompensated heart failure is associated with high rates of morbidity and mortality and it is responsible for numerous hospitalizations. The current approach to acute exacerbations is based on diuretics, vasodilators and inotropes. Compared with the impressive development of new therapeutic agents designed for other cardiovascular diseases, little progress has been observed in developing new drugs for the treatment of decompensated heart failure. Moreover, a series of controlled clinical trials failed to show a better outcome or a reduction in morbidity during treatment with inotropes, even though promising results were recently observed in controlled clinical trials with new classes of drugs, such as calcium sensitizers and nesiritide; these agents will probably modify the treatment options of decompensated heart failure in the coming years.

Original languageEnglish
JournalItalian Heart Journal
Volume4 Suppl 2
Publication statusPublished - May 2003

Fingerprint

Heart Failure
Controlled Clinical Trials
Morbidity
Brain Natriuretic Peptide
Therapeutics
Vasodilator Agents
Diuretics
Pharmaceutical Preparations
Hospitalization
Cardiovascular Diseases
Calcium
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Infusion therapy in severe heart failure. A reappraisal. / Campana, Carlo; Scelsi, Laura; Serio, Alessandra.

In: Italian Heart Journal, Vol. 4 Suppl 2, 05.2003.

Research output: Contribution to journalArticle

@article{27a21a4152eb407eb68d1f430e77b1cc,
title = "Infusion therapy in severe heart failure. A reappraisal.",
abstract = "Decompensated heart failure is associated with high rates of morbidity and mortality and it is responsible for numerous hospitalizations. The current approach to acute exacerbations is based on diuretics, vasodilators and inotropes. Compared with the impressive development of new therapeutic agents designed for other cardiovascular diseases, little progress has been observed in developing new drugs for the treatment of decompensated heart failure. Moreover, a series of controlled clinical trials failed to show a better outcome or a reduction in morbidity during treatment with inotropes, even though promising results were recently observed in controlled clinical trials with new classes of drugs, such as calcium sensitizers and nesiritide; these agents will probably modify the treatment options of decompensated heart failure in the coming years.",
author = "Carlo Campana and Laura Scelsi and Alessandra Serio",
year = "2003",
month = "5",
language = "English",
volume = "4 Suppl 2",
journal = "Italian Heart Journal",
issn = "1129-471X",
publisher = "Societa Italiana di Cardiologia",

}

TY - JOUR

T1 - Infusion therapy in severe heart failure. A reappraisal.

AU - Campana, Carlo

AU - Scelsi, Laura

AU - Serio, Alessandra

PY - 2003/5

Y1 - 2003/5

N2 - Decompensated heart failure is associated with high rates of morbidity and mortality and it is responsible for numerous hospitalizations. The current approach to acute exacerbations is based on diuretics, vasodilators and inotropes. Compared with the impressive development of new therapeutic agents designed for other cardiovascular diseases, little progress has been observed in developing new drugs for the treatment of decompensated heart failure. Moreover, a series of controlled clinical trials failed to show a better outcome or a reduction in morbidity during treatment with inotropes, even though promising results were recently observed in controlled clinical trials with new classes of drugs, such as calcium sensitizers and nesiritide; these agents will probably modify the treatment options of decompensated heart failure in the coming years.

AB - Decompensated heart failure is associated with high rates of morbidity and mortality and it is responsible for numerous hospitalizations. The current approach to acute exacerbations is based on diuretics, vasodilators and inotropes. Compared with the impressive development of new therapeutic agents designed for other cardiovascular diseases, little progress has been observed in developing new drugs for the treatment of decompensated heart failure. Moreover, a series of controlled clinical trials failed to show a better outcome or a reduction in morbidity during treatment with inotropes, even though promising results were recently observed in controlled clinical trials with new classes of drugs, such as calcium sensitizers and nesiritide; these agents will probably modify the treatment options of decompensated heart failure in the coming years.

UR - http://www.scopus.com/inward/record.url?scp=2142844736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142844736&partnerID=8YFLogxK

M3 - Article

VL - 4 Suppl 2

JO - Italian Heart Journal

JF - Italian Heart Journal

SN - 1129-471X

ER -